SCHEDULE: Battery Ventures Affiliates Secure Key Shareholder Support for Enzo Biochem Merger

Battery Ventures affiliates have filed a Schedule 13D, disclosing beneficial ownership of 21.8% of Enzo Biochem, Inc. common stock through voting agreements supporting a merger with Bethpage Parent, Inc.

Summary

• Battery Ventures entities and managing members (Reporting Persons) have filed a Schedule 13D regarding Enzo Biochem, Inc.
• The filing indicates beneficial ownership of 11,575,824 shares of Enzo Biochem's Common Stock, representing 21.8% of the total outstanding shares.
• This beneficial ownership stems from voting and support agreements entered into on June 23, 2025, by Enzo Biochem's officers, directors, and its largest shareholder, Harbert Discovery Fund, LP and its affiliates (collectively, "Voting Parties").
• The Voting Parties have agreed to vote their shares in favor of the merger of Enzo Biochem with Bethpage Merger Sub, Inc., a wholly-owned subsidiary of Bethpage Parent, Inc.
• Bethpage Parent, Inc. and Bethpage Merger Sub, Inc. are affiliates of Battery Ventures XIV, L.P., Battery Ventures XIV-EF, L.P., and Battery Investment Partners XIV, L.P.
• The Voting Agreements also prohibit the transfer of shares (with exceptions), granting proxies, or exercising dissenters' rights.
• No separate consideration was paid for the Voting Agreements.
• The 11,575,824 shares include 656,787 shares from stock options and 79,780 shares from restricted stock units exercisable or settlable within 60 days of June 30, 2025.

Sentiment

Score: 7

Explanation: The filing indicates a significant step towards a corporate acquisition, with strong shareholder support secured through voting agreements. This generally signals progress and reduced uncertainty regarding the transaction's completion, which is positive for the acquiring entity and potentially for the target's shareholders if the merger terms are favorable (though terms are not detailed here).

Positives

• Significant shareholder support (21.8% of outstanding shares) secured for the proposed merger, increasing the likelihood of its successful completion.
• The merger, if completed, would transition Enzo Biochem into a wholly-owned subsidiary of Bethpage Parent, Inc., an affiliate of Battery Ventures, potentially streamlining operations or strategic direction.

Risks

• The merger is subject to terms and conditions set forth in the Merger Agreement, implying that it is not yet a certainty and could still fail to close if conditions are not met.
• The Reporting Persons disclaim beneficial ownership of the shares covered by the Voting Agreements, indicating they do not have the power to dispose of the shares or cause stock options to be exercised, which limits their direct control over these specific shares beyond the voting agreement.

Future Outlook

The filing indicates a clear path towards the acquisition of Enzo Biochem, Inc. by Bethpage Parent, Inc. (an affiliate of Battery Ventures) through a merger, subject to the terms and conditions of the Merger Agreement. The voting agreements from key shareholders and management signal strong support for this transaction.

Industry Context

This filing represents a significant step in the potential acquisition of a publicly traded company (Enzo Biochem, Inc.) by a private equity-backed entity (Bethpage Parent, Inc., affiliated with Battery Ventures). Such transactions are common in industries undergoing consolidation or where private equity firms see opportunities for value creation through operational improvements or strategic shifts.

Corporate Governance

Related Party Transactions

• Bethpage Parent, Inc. and Bethpage Merger Sub, Inc., the entities acquiring Enzo Biochem, are affiliates of the Battery Ventures reporting persons. This constitutes a related party transaction in the context of the acquisition.

Stakeholder Impact

• Shareholders: The merger will result in Enzo Biochem becoming a wholly-owned subsidiary, implying that current public shareholders will receive consideration for their shares (terms not specified in this 13D). The voting agreements from key shareholders indicate their alignment with this outcome.
• Employees: The merger could lead to changes in management, operations, or corporate structure, potentially impacting employees, though no specifics are provided.
• Management: Current officers and directors are part of the Voting Parties, indicating their alignment with the merger.

Next Steps

• Completion of the merger of Merger Sub with and into Enzo Biochem, Inc., subject to the terms and conditions of the Merger Agreement.
• Voting by shareholders on the adoption of the Merger Agreement, as per the Voting Agreements.

Key Dates

Recommendation

Keywords

Enzo Biochem, Battery Ventures, Schedule 13D, Merger Agreement, Voting Agreement, Beneficial Ownership, Corporate Acquisition, Private Equity, Biotech, Healthcare